The role of receptors in the HIV-1 entry process

European Journal of Medical Research

Volumn 12, Issue 9, 2007, Pages 391-396

  Jones, Rachael ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Highly active antiretroviral therapy; HIV; HIV entry inhibitors

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); AMD 070; AMD 887; ANTIRETROVIRUS AGENT; APLAVIROC; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; PLACEBO; RITONAVIR; T 1249; TNX 355; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOTENSION; LIVER TOXICITY; MORTALITY; NAUSEA; NONHUMAN; PHENOTYPE; QT INTERVAL; RECEPTOR BLOCKING; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIGENS, CD4; DRUG DESIGN; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 35548983905     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gottlieb M, Schroff R, Schanker H, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular deficiency. N Engl J Med 1981; 305:1425-1431.
2. No authors. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30:305-308.
3. Chermann J, Barre-Sinoussi F, Dauguet C, et al. Isolation of a new retrovirus in a patient at risk for acquired immunodeficiency syndrome. Antibiot Chemother. 1983; 32:48-53.
4. Nielsen C, Pedersen C, Lundgten JD, et al. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS. 1993;7(8):1035-40.
5. Daar ES, Li XL, Moudgil T, et al. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1990; 87(17):6574-8.
6. Hanna G, Lalezari J, Hellinger J, et al. Antiviral activity, safety and tolerability of a novel oral small molecule HIV-1 attachment inhibitor BMS-488043 in HIV-1 infected subjects. 11th Conference on Reroviruses and Opportunistic Infections. San Francisco, CA, Feb 2004 [Abstract 141].
7. Kuritzkes D, Jacobson J, Powderly W, et al. Safety and preliminary anti-HIV activity of an anti-CD4 mAb (TNX-355; formerly Hu5A8) in HIV-infected patients. 10th Conference on Reroviruses and Opportunistic Infections. Boston, MA, Feb 2003 [Abstract 13].
8. Norris D et al TNX 355 in combination with OBR achieves statistically significant viral load reduction and CD4 count increase when compared with OBR alone in a phase 2 study at 48 weeks. Sixteenth IAS Conference Toronto abstract THLB0218, 2006.
9. Jacobson J, Israel R, Lowy, et al. Treatment of advanced human immunodeficiency type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004; 48: 423-29.
10. Stewart GJ, Ashton LJ, Biti RA, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term nonprogressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS. 1997; 11(15):1833-8.
11. Gulick R, Su Z, Flexner C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 2007.
12. M McHale, Abel S, Russel D, et al. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). Abstract TuOa0204 (oral). 3rd IAS Conference on HIV Pathogenesis and Treatment. July 24-27, 2005. Rio de Janeiro, Brazil.
13. Abel S, Russell D, Ridgeway C et al. Overview of the drug-drug interaction data for Miraviroc (UK-427, 857). 2005; 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec. Abstract 76.
14. Lalezari J, Goodrich J, DeJesus E et al. Efficacy and safety of maraviroc plus optimised background therapy in viraemic ART experienced patients infected with CCR5 tropic HIV-1:24 week results from a phase 2b/ 3 study in the US and Canada 14th CROI 2007.
15. Nelson M, Fatkenheur G, Konourina I et al Efficacy and safety of maraviroc plus optimised background therapy in viraemic ART experienced patients infected with CCR5 tropic HIV-1:24 week results from a phase 2b/ 3 study in Europe, Australia and North America: 24 week results CROI 2007.
16. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/lamivudine), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 2007.
17. Schols D, Claes S, De Clerq E, et al. AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 2002 [Abstract 2].
18. Stone N, Dunaway S, Flexner C, et al. Biologic activity of an orally bioavailable CXCR4 antagonist in human subjects. Program and Abstracts of the XV International AIDS Conference. Bangkok, Thailand, 2004 [Abstract TuPeB4475].
19. Hazuda D. A novel HIV-1 integrase inhibitor mediates sustained suppression of viral replication and CD4 deplenon in a SHIV rhesus macaque model of infection. Antiviral Ther 2002; 7 (Suppl. 1): S3.